MAPT and Brain atrophy: Human studies with autosomal dominant forms of AD suggest that Aβ levels begin to change as early as 25–30 years prior to symptom onset, followed by tau pathology about 15 years prior to symptom onset, cerebral hypometabolism, brain atrophy, and cognitive and functional deficits [9, 29].